WASHINGTON, June 1, 2023
/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq:
VNDA) today announced participation at SLEEP 2023, to be held in
Indianapolis, IN from June 3 – 7, 2023.
The following will be presented:
June 5, 2023
Presentation Title: "Melanopsin Genetic Variants and Delayed
Sleep Phenotype – Whole Genome Sequencing Analysis"
Poster Number: 94
Presenter: Dr. Sandra Paulina
Smieszek, Head of Genetics
Poster Session Presentation Time: 5:00
PM – 6:00 PM ET
June 6, 2023
Presentation Title: "Dim Light Melatonin Onset Analysis in
Individuals Diagnosed with Delayed Sleep-Wake Phase Disorder
(DSWPD)"
Poster Number: 307
Presenter: Dr. Sandra Paulina
Smieszek, Head of Genetics
Poster Session Presentation Time: 12:00
PM – 1:15 PM ET
Presentation Title: "Effect of Iloperidone on Sleep Symptoms in
Bipolar Patients with Manic and Mixed Episodes: A Randomized,
Placebo Controlled Study"
Poster Number: 372
Presenter: Dr. Sandra Paulina
Smieszek, Head of Genetics
Poster Session Presentation Time: 5:00
PM – 6:00 PM ET
For more information on SLEEP 2023, please refer to
https://www.sleepmeeting.org/.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on
the development and commercialization of innovative therapies to
address high unmet medical needs and improve the lives of patients.
For more on Vanda Pharmaceuticals Inc., please visit
www.vandapharma.com and follow us on Twitter @vandapharma.
Corporate Contact:
Kevin
Moran
Senior Vice President, Chief Financial Officer and
Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Elizabeth Van Every
Head of Corporate Affairs
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
View original
content:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-presentations-at-sleep-2023-301840794.html
SOURCE Vanda Pharmaceuticals Inc.